• Polybiocept GmbH


Takura’s ownership interest: 23 %

The company works with immuno-oncology and is a clinical stage biotech firm with an initial research focus on difficult-to-treat cancer tumours, such as glioblastoma and pancreas cancer. 16 patients have so far been treated in collaboration with Krankenhaus Nordwest in Germany. PBC was founded in 2013 based on the research conducted at Karolinska Institutet in Sweden and in collaboration with other world leading cancer research institutions. Polybiocept´s main technology is based on Tumour Infiltrating Lymphocytes (TILs).

Business model

Product for cell expansion and treatment methods for different cancer types which can be used in own clinics or by partners with licence agreements.